Comparative Pharmacology
Head-to-head clinical analysis: PIRMELLA 7 7 7 versus TRI LEGEST FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIRMELLA 7 7 7 versus TRI LEGEST FE.
PIRMELLA 7/7/7 vs TRI-LEGEST FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pirmelevir is a selective inhibitor of the hepatitis C virus (HCV) NS5A protein, essential for viral replication and assembly. It disrupts the double-membrane vesicles where HCV RNA replication occurs.
Tri-Legest FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It prevents ovulation by inhibiting gonadotropin release (FSH and LH) and alters cervical mucus and endometrial lining to impede sperm penetration and implantation.
PIRMELLA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.180/0.215/0.250 mg in a triphasic regimen. One tablet daily for 28 days, with 7 inactive tablets.
One tablet orally once daily for 28-day cycle: 21 days active tablets (norethindrone/ethinyl estradiol) followed by 7 days placebo. For contraception only.
None Documented
None Documented
Terminal elimination half-life: 8-10 hours. Clinically, steady-state reached in 2-3 days.
Norethindrone: 7-8 hours; Ethinyl estradiol: 18 hours (terminal). Steady-state reached after 7 days; clinical contraceptive efficacy requires consistent dosing.
Renal: 70% unchanged; fecal: 30% as metabolites.
Renal: ~60% (metabolites), Fecal: ~30% (metabolites), Biliary: minor (~5% as conjugates)
Category C
Category C
Oral Contraceptive
Oral Contraceptive